when will tirzepatide get fda approval Grants a New Indication for Obesity Management FDA Approves Mounjaro (tirzepatide) Injection

This phenomenon, known as the incretin effect, is greatly reduced in diabetics, a difference that led to the development of analogues of incretin GLP-1 and GIP

The breakout above the historical high resistance level reinforces the bullish scenario and signals trend continuation

You're satisfied with 2223% average weight loss for patients at BMI 3035, this is often sufficient to achieve target outcomes

Despite challenges like high treatment costs, the market is anticipated to expand further, fueled by increasing clinical evidence, new regulatory approvals for additional indications, and the development of more affordable alternatives

When you stop the medication - benefits and efficacy is lost